These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 22926753)
1. SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells. Wang CT; Lin CS; Shiau CW; Chu PY; Hsiao CC; Chiang YL; Tai WT; Chen KF J Orthop Res; 2013 Feb; 31(2):335-42. PubMed ID: 22926753 [TBL] [Abstract][Full Text] [Related]
2. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer. Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071 [TBL] [Abstract][Full Text] [Related]
3. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3. Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751 [TBL] [Abstract][Full Text] [Related]
4. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Chen KF; Su JC; Liu CY; Huang JW; Chen KC; Chen WL; Tai WT; Shiau CW Cancer Lett; 2012 Aug; 321(1):27-35. PubMed ID: 22465052 [TBL] [Abstract][Full Text] [Related]
5. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226 [TBL] [Abstract][Full Text] [Related]
6. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479 [TBL] [Abstract][Full Text] [Related]
7. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Liu CY; Tseng LM; Su JC; Chang KC; Chu PY; Tai WT; Shiau CW; Chen KF Breast Cancer Res; 2013; 15(4):R63. PubMed ID: 23938089 [TBL] [Abstract][Full Text] [Related]
8. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937 [TBL] [Abstract][Full Text] [Related]
9. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225 [TBL] [Abstract][Full Text] [Related]
10. STAT3 inhibitor, cucurbitacinĀ I, is a novel therapeutic agent for osteosarcoma. Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells. Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011 [TBL] [Abstract][Full Text] [Related]
12. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308 [TBL] [Abstract][Full Text] [Related]
13. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138 [TBL] [Abstract][Full Text] [Related]
15. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051 [TBL] [Abstract][Full Text] [Related]
16. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456 [TBL] [Abstract][Full Text] [Related]